SEQUOIA CAPITAL DUBBED COVID THE BLACK SWAN OF 2020.

GZI is a different kind of animal.



PURPOSE

GZI uses alternative financial data to help customers get shorty and prevent meme-stock volatility



PROBLEM

Global economic trends have changed permanently



COVID impacts the lives of people globally. Pew Research Center reported that roughly half of non-retired adults say the economic consequences of COVID will complicate their financial goals.



Many investors still rely heavily on traditional data that lack transparency, streamlined delivery, and alternative viewpoints.



The respective five year returns for AI/ML, systematic, and normal hedge funds: 7.6%, 5.22%, 6.03%.



SOLUTION

GZI delivers results through data



GZI delivers cutting edge alternative data to users in search of higher returns and less volatility. Alternative data helps investors get more accurate, faster, and granular insights/metrics.

Our 2020 & 2021 **RESULTS**

2020:

51% higher than robo advisors

2021:

23% higher than robo advisors

Consistently on par with the top hedge funds in the world



We resell the industry agnostic and sector specific alternative data used to outperform some of the top funds on Wall St., back to clients across more than 4 continents and 16 countries.



MARKET

We address emerging trends within existing markets

Alternative Data

Defensive moat within B2B opportunity. Projected bottoms-up TAM is \$15m in 18 months.

Cryptocurrency AUM

Cryptocurrency is being regulated the same as financial services

Total Hedge Fund AUM

Massive existing TAM

\$3.8B
Cryptocurrency
AUM

\$3.5MAlternative Data


\$3.2TAUM
Worldwide



COMPETITION

GZI works at the intersection of existing markets

- Flexible Adoption
- Data-driven products mimic results without regulatory burdens
- Our data delivers hedge-fund results at start-up pricing





PRODUCT

Cutting-edge data with an engaging interface



See how our data helps you achieve your goal across 4 continents and 16 countries. C21 supplies press 4-continents and 16 countries. C21 supplies pressure and data according to our backlest and lets you build datasets your way.





North America

Stock Eichanges Include: New York Stock Eichange (NYSE), Nasdard Technology (NASDAQ), Mexico (MEXI), Canada (TSE), Canadian Venture (TSXV)



Western Europe

Stock Exchanges Include: London (LSE). France (SBF) Portugal (BVL), Italy (BMV). Venna (VSE), Suits Bechanic Bourse (BbS), SX Suits (VRTX)



Groundbreaking data

Beautiful design

Here's What People Are Saying



Shawn C

"CZIs proprietary strategies enabled me to achieve a return of 56,05% on my portfolio from October 2019 to March 2021, 18 definitely be conserving his methods for future decisions."



Wonkyung Lee

1 met Sean at dente with some Kiends back in November 2019 where, he inhaduced us to his company and its trading methodology (Whin I asked for a name to invest is, he mentioned Moderna (MSRA) as a solid pharma company. At the time, it was trading at \$18. My husband and I solil about Sean every time we see the stock achieve new highs."



Key revenue channels

Data



Provides customers the same trading ability without overstepping regulations



Structured Products

Data can be restructured for cross-selling opportunities with more advanced features



Licensing Agreements



Signed NDAs from hedge funds and ETF managers





Internationally applicable solution is easily distributed worldwide



TRACTION

Customers rave about GZI predicting trends before COVID existed



GZI's proprietary strategies enabled me to achieve a return of 56.05% on my portfolio from October 2019 to March 2021. I'll definitely be conserving his methods for future decisions.

Shawn C.



I met Sean at dinner with some friends back in November 2019 where he introduced us to his company and its trading methodology. When I asked for a name to invest in, he mentioned Moderna (MRNA) as a solid pharma company. At the time, it was trading at \$18. My husband and I talk about Sean every time we see the stock achieve new highs.

Wonkyung Lee



TFAM

All-star team across sectors and networks



Sean Adler CEO, Cofounder

Screened Biotech Ventures During COVID for Alumni Angels

Outperformed 95% of Wall
St. in 2020







Matt Mandell Industry Advisor

Top Rated Mentor at Founder Institute Since 2009

2 Exits







Lexington Blood
Financial Advisor

Partner at 7BC.VC and LB Ventures

7BC.VC Invested in Superhuman Alongside Jason Calacanis







Tony MaTechnical Advisor

Raised \$13m for Benten Technologies

Chair of the Founder's Network DC Chapter







ROADMAF

GZI's continuous progress

Solidifies Positioning

Outperforms 103/107 of Wall St.'s largest hedge funds with 58% gain, including 400% on biotech



MAR 2021

Press Coverage

CEO featured in the "Top 10 Most Influential Leaders in Biotechnology", Fund Up 30% YTD



JULY 2021

Visibility and Distribution

Onboards leading VC advisor, Social Media pageviews spike 335% MoM, Finalizing GZI's rights to an ETF

Pitched Alumni Agnel Group

SEP 2020

CEO Screened Biotech Ventures for COVID

DEC 2020



Public Recognition

Interviews at CNBC,
Graduates Founder
Institute's Accelerator as
FI Select Company

JUNE 2021



Contracts and Financing

Closes \$250k from Netcapital, 2yr Development Contract with Kiwitech

AUGUST 2021





VISION

In five years, GZI's goal is to use alternative financial data for the benefit of customers around the world.



SUMMARY

Here's a quick recap of why we're amazing



Huge market opportunity

International partnerships rapidly distribute product worldwide

Finalizing rights to
an ETF launched
through Exchange
Traded Concepts



Experienced team

Industry leaders

- across sectors from leading accelerators and networks
- 2 exits, \$13m raised, leading investors



Successful product launch

\$250k Reg CF

- Offering on Netcapital, a Top 5 Platform
- 2yr development contract with Kiwitech



Raising \$750k by Janurary 2022

Fund and launch

- → GZI 2.0 and 3.0 to reach
- → 142 contracts

